X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program. The two have been working together since 2012 in a multitarget collaboration. Under the latest deal, gets an undisclosed upfront fee and milestones down the line in exchange for some small-molecule candidates that target cardiovascular disease. More